SCHEMBL1619196

SCHEMBL1619196

C[Si](C)(C)C#C/C=C/CBr

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1619198 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
SCHEMBL11911402 0.77
SCHEMBL1619244 0.75
SCHEMBL1619248 0.75
SCHEMBL9284610 0.74
SCHEMBL3286850 0.74
SCHEMBL3286849 0.74
SCHEMBL12389699 0.70
SCHEMBL16977026 0.67
SCHEMBL14714698 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288549-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF UNIVERSITY HEALTH NETWORK (CA) 2025-09-18 US disclosed
WO-2023205908-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF UNIVERSITY HEALTH NETWORK (CA) 2023-11-02 WO disclosed
US-7994346-B2 such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-09 US disclosed
US-7928255-B2 Intermediates for the preparation of lipoxin A4 analogs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-04-19 US disclosed
EP-1472209-B1 LIPOXIN A4 ANALOGS BAYER SCHERING PHARMA AG (DE) 2009-03-04 EP disclosed
US-7223798-B2 Lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-29 US disclosed
US-20070105949-A1 Intermediates for the preparation of lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-10 US disclosed
US-20070037864-A1 Intermediates for the preparation of lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2007-02-15 US disclosed
US-6831186-B2 Antiinflammatory agents; autoimmune disease SCHERING AKTIENGESELLSCHFT (DE) 2004-12-14 US disclosed
EP-1472209-A2 LIPOXIN A4 ANALOGS SCHERING AKTIENGESELLSCHAFT (DE) 2004-11-03 EP disclosed
US-20040162433-A1 Lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2004-08-19 US disclosed
US-20030139376-A1 Lipoxin A4 analogs SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-24 US disclosed
WO-2003040080-A2 LIPOXIN A4 ANALOGS SCHERING AKTIENGESELLSCHAFT (DE) 2003-05-15 WO disclosed
US-5439932-A Anticholesterol agents BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed
US-5306728-A Substituted amine derivatives having antihyperlipemia activity BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-04-26 US disclosed
US-4542022-A FUNGICIDE SANDOZ LTD. (CH) 1985-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037864-A1 Intermediates for the preparation of lipoxin A4 analogs LTB4R, LTB4R2, LTA4H ALDH1A1 1336/4885TSHR 569/4885
US-20040162433-A1 Lipoxin A4 analogs LTA4H, LTB4R, LTB4R2 ALDH1A1 1459/4885TSHR 862/4885
US-20250288549-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF LTB4R, LTB4R2, ALOX15B ALDH1A1 3596/4885TSHR 1182/4885
US-20030139376-A1 Lipoxin A4 analogs LTA4H, LTB4R, LTB4R2 ALDH1A1 1459/4885TSHR 862/4885
US-20070105949-A1 Intermediates for the preparation of lipoxin A4 analogs LTB4R, LTB4R2, LTC4S ALDH1A1 1140/4885TSHR 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.